Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin for Esophageal Barrier Function in GERD
NCT02226484Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Aug 2014
- Primary completion
- May 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quercetin in gastroesophageal reflux disease (GERD), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Expression of claudin-4 in esophageal squamous epithelium (ESE) at 6 weeks. Started Aug 2014; status: completed.
02
Drugs
quercetin
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02226484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226484.